Accounting related to revenue recognition issues has been one of the thornier subjects tripping up report preparers in recent ...

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss ...

Running a 2,000 patient study, with average risk patients in the U.S., to read out by the end of 2025 (eAArly DETECT 2). With eAArly DETECT 2, the Company addresses FDA feedback and prepares for a new ...

A recent survey conducted as part of the launch of the National Financial Education Program (Fin-Ed) in Liberia has revealed ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the ...

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Good afternoon ladies and gentlemen and thank you for standing by.

PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, demonstrating ...

Gain insights from ClearSign's Q4 2024 earnings call: record revenue growth, innovative product launches, strategic industry partnerships, and future plans.

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook ...

Thank you, operator. Good afternoon, and thank you for joining us on today's earnings conference call and webcast to discuss Penguin Solutions' second quarter fiscal 2025 results. On the call today ...

According to a new NerdWallet survey, 9% of Americans are attending a wedding out of town this summer. Here’s how they can ...